125 related articles for article (PubMed ID: 32693135)
1. Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy.
Amirani E; Hallajzadeh J; Asemi Z; Mansournia MA; Yousefi B
Int J Biol Macromol; 2020 Dec; 164():456-467. PubMed ID: 32693135
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
3. PI-103 and Quercetin Attenuate PI3K-AKT Signaling Pathway in T- Cell Lymphoma Exposed to Hydrogen Peroxide.
Maurya AK; Vinayak M
PLoS One; 2016; 11(8):e0160686. PubMed ID: 27494022
[TBL] [Abstract][Full Text] [Related]
4. PI3K and AKT: Unfaithful Partners in Cancer.
Faes S; Dormond O
Int J Mol Sci; 2015 Sep; 16(9):21138-52. PubMed ID: 26404259
[TBL] [Abstract][Full Text] [Related]
5. The phosphatidylinositol 3-kinase/Akt and c-Jun N-terminal kinase signaling in cancer: Alliance or contradiction? (Review).
Zhao HF; Wang J; Tony To SS
Int J Oncol; 2015 Aug; 47(2):429-36. PubMed ID: 26082006
[TBL] [Abstract][Full Text] [Related]
6. Hedyotis diffusa Willd inhibits proliferation and induces apoptosis of 5‑FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway.
Li Q; Lai Z; Yan Z; Peng J; Jin Y; Wei L; Lin J
Mol Med Rep; 2018 Jan; 17(1):358-365. PubMed ID: 29115462
[TBL] [Abstract][Full Text] [Related]
7. Chitin and Chitosan Derivatives as Biomaterial Resources for Biological and Biomedical Applications.
Satitsri S; Muanprasat C
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339290
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Bitting RL; Armstrong AJ
Endocr Relat Cancer; 2013 Jun; 20(3):R83-99. PubMed ID: 23456430
[TBL] [Abstract][Full Text] [Related]
9. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation.
Bai C; Yang X; Zou K; He H; Wang J; Qin H; Yu X; Liu C; Zheng J; Cheng F; Chen J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):573-84. PubMed ID: 26935715
[TBL] [Abstract][Full Text] [Related]
10. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
11. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
12. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling.
Zheng YB; Xiao GC; Tong SL; Ding Y; Wang QS; Li SB; Hao ZN
World J Gastroenterol; 2015 Jun; 21(23):7197-207. PubMed ID: 26109806
[TBL] [Abstract][Full Text] [Related]
13. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
14. Isoforms S and L of MRPL33 from alternative splicing have isoform‑specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway.
Li J; Feng D; Gao C; Zhang Y; Xu J; Wu M; Zhan X
Int J Oncol; 2019 May; 54(5):1591-1600. PubMed ID: 30816492
[TBL] [Abstract][Full Text] [Related]
15. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents.
Sun H; Wang Z; Yakisich JS
Anticancer Agents Med Chem; 2013 Sep; 13(7):1048-56. PubMed ID: 23293890
[TBL] [Abstract][Full Text] [Related]
16. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor efficacy of phellamurin in osteosarcoma cells: Involvement of the PI3K/AKT/mTOR pathway.
Zhang H; Jiang H; Zhang H; Liu J; Hu X; Chen L
Eur J Pharmacol; 2019 Sep; 858():172477. PubMed ID: 31228450
[TBL] [Abstract][Full Text] [Related]
18. Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma.
Zhu J; Wang M; Cao B; Hou T; Mao X
Curr Med Chem; 2014; 21(27):3173-87. PubMed ID: 24934342
[TBL] [Abstract][Full Text] [Related]
19. PI3K/Akt signaling in osteosarcoma.
Zhang J; Yu XH; Yan YG; Wang C; Wang WJ
Clin Chim Acta; 2015 Apr; 444():182-92. PubMed ID: 25704303
[TBL] [Abstract][Full Text] [Related]
20. Marine compounds targeting the PI3K/Akt signaling pathway in cancer therapy.
Wei J; Gou Z; Wen Y; Luo Q; Huang Z
Biomed Pharmacother; 2020 Sep; 129():110484. PubMed ID: 32768966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
